Columbus Circle Investors Has $5.95 Million Stock Position in CryoPort Inc (NASDAQ:CYRX)
Columbus Circle Investors increased its holdings in shares of CryoPort Inc (NASDAQ:CYRX) by 2.4% in the 4th quarter, HoldingsChannel reports. The firm owned 361,607 shares of the consumer goods maker’s stock after acquiring an additional 8,417 shares during the period. Columbus Circle Investors’ holdings in CryoPort were worth $5,952,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in CryoPort by 7.1% during the second quarter. BlackRock Inc. now owns 2,048,518 shares of the consumer goods maker’s stock worth $37,529,000 after purchasing an additional 135,471 shares during the period. Vanguard Group Inc. grew its stake in CryoPort by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,704,620 shares of the consumer goods maker’s stock worth $31,228,000 after purchasing an additional 203,846 shares during the period. Chevy Chase Trust Holdings Inc. grew its stake in CryoPort by 174.4% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 1,650,514 shares of the consumer goods maker’s stock worth $26,994,000 after purchasing an additional 1,049,090 shares during the period. TimesSquare Capital Management LLC acquired a new stake in CryoPort during the third quarter worth approximately $22,002,000. Finally, Victory Capital Management Inc. grew its stake in CryoPort by 530.3% during the second quarter. Victory Capital Management Inc. now owns 1,186,220 shares of the consumer goods maker’s stock worth $21,731,000 after purchasing an additional 998,020 shares during the period. 74.24% of the stock is owned by institutional investors and hedge funds.
Several research firms recently commented on CYRX. Needham & Company LLC decreased their target price on CryoPort from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, January 13th. BidaskClub raised CryoPort from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 16th. ValuEngine cut CryoPort from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. B. Riley began coverage on CryoPort in a research note on Friday, January 10th. They set a “buy” rating and a $26.00 target price for the company. Finally, Stephens began coverage on CryoPort in a research note on Tuesday, January 7th. They set an “overweight” rating and a $21.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.25.
CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, November 7th. The consumer goods maker reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02. CryoPort had a negative return on equity of 26.50% and a negative net margin of 64.63%. The firm had revenue of $9.58 million during the quarter, compared to analysts’ expectations of $9.49 million. During the same quarter last year, the firm posted ($0.07) earnings per share. The company’s revenue for the quarter was up 81.1% compared to the same quarter last year. Research analysts forecast that CryoPort Inc will post -0.61 EPS for the current year.
In other news, CEO Jerrell Shelton acquired 3,356 shares of CryoPort stock in a transaction on Tuesday, November 12th. The stock was purchased at an average price of $15.56 per share, with a total value of $52,219.36. Also, Director Richard J. Berman sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.27, for a total value of $152,700.00. Insiders sold 150,036 shares of company stock valued at $2,224,533 in the last three months. Insiders own 11.00% of the company’s stock.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Further Reading: Guidelines for Successful Channel Trading
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort Inc (NASDAQ:CYRX).
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.